These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34956861)

  • 61. The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality.
    Turinetto M; Scotto G; Tuninetti V; Giannone G; Valabrega G
    Front Oncol; 2021; 11():689829. PubMed ID: 34195090
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    Han Y; Li CW; Hsu JM; Hsu JL; Chan LC; Tan X; He GJ
    Am J Cancer Res; 2019; 9(4):800-815. PubMed ID: 31106005
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
    Nizialek E; Antonarakis ES
    Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors.
    Dickson BD; Wong WW; Wilson WR; Hay MP
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31010230
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 68. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
    Javle M; Curtin NJ
    Ther Adv Med Oncol; 2011 Nov; 3(6):257-67. PubMed ID: 22084640
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity.
    Horton JK; Wilson SH
    Front Oncol; 2013 Sep; 3():257. PubMed ID: 24137565
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21.
    Kim DS; Camacho CV; Nagari A; Malladi VS; Challa S; Kraus WL
    Mol Cell; 2019 Sep; 75(6):1270-1285.e14. PubMed ID: 31351877
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ovarian cancer resistance to PARPi and platinum-containing chemotherapy.
    Summey R; Uyar D
    Cancer Drug Resist; 2022; 5(3):637-646. PubMed ID: 36176755
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; Jeong AD; Guntupalli SR; Behbakht K; Gbaja V; Arnoult N; Chuong EB; Bitler BG
    bioRxiv; 2023 Feb; ():. PubMed ID: 36865165
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.
    Shih DJH; Chen MK; Yin J; McGrail DJ; Dai H; Wei R; Zhang J; Zheng WJ; Do KA; Yang L; Hung MC; Lin SY
    Am J Cancer Res; 2022; 12(1):337-354. PubMed ID: 35141022
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor scheduling.
    Strobl M; Martin AL; West J; Gallaher J; Robertson-Tessi M; Gatenby R; Wenham R; Maini P; Damaghi M; Anderson A
    bioRxiv; 2023 Mar; ():. PubMed ID: 36993591
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Correction: PARP targeted Auger emitter therapy with [
    Sankaranarayanan RA; Florea A; Allekotte S; Vogg ATJ; Maurer J; Schäfer L; Bolm C; Terhorst S; Classen A; Bauwens M; Morgenroth A; Mottaghy FM
    EJNMMI Res; 2023 Feb; 13(1):12. PubMed ID: 36763205
    [No Abstract]   [Full Text] [Related]  

  • 79. Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3.
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38986545
    [No Abstract]   [Full Text] [Related]  

  • 80. Editorial: Impact of genome instability on human health.
    Ray S; Chakrabarty S; Chaudhuri AR
    Front Mol Biosci; 2023; 10():1243968. PubMed ID: 37533677
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.